» Articles » PMID: 14699484

The DeltaF508 Mutation Results in Loss of CFTR Function and Mature Protein in Native Human Colon

Overview
Specialty Gastroenterology
Date 2003 Dec 31
PMID 14699484
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Deletion of the codon for phenylalanine at position 508 (DeltaF508) is the most frequent disease-causing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. In heterologous cells, defective processing of the DeltaF508 protein results in endoplasmic reticulum retention, proteolytic degradation, and absence of adenosine 3',5'-cyclic monophosphate (cAMP)-dependent plasma membrane Cl(-) conductance. However, data with respect to the processing block of DeltaF508 protein in native epithelia are limited and conflicting.

Methods: To characterize both the fate and function of DeltaF508 protein in a native epithelium, we measured CFTR-mediated Cl(-) secretion, localization of the CFTR protein, and CFTR maturation in rectal biopsy specimens from normal individuals and DeltaF508 homozygous patients with cystic fibrosis (CF).

Results: Ussing chamber studies showed that cAMP-dependent and cholinergic Cl(-) secretion was absent from rectal tissues freshly excised from DeltaF508 homozygous patients with CF. By immunohistochemistry, we detected wild-type but not DeltaF508 CFTR at the luminal membrane of crypt colonocytes. By sequential immunoprecipitation and immunoblotting analyses, mature CFTR protein was detected in normal but not in DeltaF508 homozygous tissues.

Conclusions: Collectively, these data show that there is insufficient maturation and transport of DeltaF508 CFTR from the endoplasmic reticulum to the apical membrane to support CFTR-mediated Cl(-) secretion in the CF colon.

Citing Articles

Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium.

Graeber S, Sommerburg O, Yu Y, Berges J, Hirtz S, Scheuermann H Front Pharmacol. 2025; 16:1537095.

PMID: 40066329 PMC: 11891205. DOI: 10.3389/fphar.2025.1537095.


Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years.

Berges J, Graeber S, Hammerling S, Yu Y, Krumpelmann A, Stahl M Front Pharmacol. 2023; 14:1188051.

PMID: 37324488 PMC: 10266342. DOI: 10.3389/fphar.2023.1188051.


The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators.

Chen J, Thrasher K, Fu L, Wang W, Aghamohammadzadeh S, Wen H Am J Physiol Lung Cell Mol Physiol. 2023; 324(6):L756-L770.

PMID: 37014818 PMC: 10202470. DOI: 10.1152/ajplung.00038.2023.


Personalized medicine approaches in cystic fibrosis related pancreatitis.

Mun K, Nathan J, Jegga A, Wikenheiser-Brokamp K, Abu-El-Haija M, Naren A Am J Transl Res. 2022; 14(10):7612-7620.

PMID: 36398272 PMC: 9641468.


Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease.

Centorame A, Dumut D, Youssef M, Ondra M, Kianicka I, Shah J Front Pharmacol. 2022; 13:876842.

PMID: 35668939 PMC: 9163687. DOI: 10.3389/fphar.2022.876842.